Aging Clocks Catalog · For buyers and repeat testers
What a biological-age test buys you
Four contrasting offerings show why the assay, algorithm, report, advice service and data contract should never be treated as one validated claim.
A dated comparison, not an endorsement. These four contrasting offerings were reviewed on 28 September 2026, without checkout, account creation, sample submission or seller contact. Displayed US-facing dollar prices are not delivered quotes. A readable listing does not establish current fulfillment; an unknown term is not evidence that the seller has no policy.
The assay measures a specimen. The model estimates a target. The report selects and labels outputs. A protein- or organ-looking result can be a prediction, not a direct measurement.
A consultation, membership or action programme adds a service. A model publication does not establish that the purchased package improves decisions or health.
What is measured—and what is inferred?
| Offering and assay | Named outputs / service | Connected evidence and unresolved equivalence |
|---|---|---|
| TruDiagnostic · TruAge | Finger-prick blood DNA methylation. OMICmAge, SYMPHONYAge and DunedinPACE are named outputs; organ/protein/function-looking results may be inferred rather than assayed. [C01] | Peer-reviewed OMICmAge, published Systems Age and DunedinPACE research support model-specific claims. The purchased array, preprocessing, missing-feature policy and each report/model release still need identification. Independent current-service change error and package benefit remain unestablished. [M05; M21; M22] |
| GlycanAge | Finger-prick blood IgG glycans, age-related indices and interpretation consultation—not methylation, total-plasma glycomics or GlycA. [C04] | Original glycan-age evidence does not pin the deployed coefficients/reference or validate a current decision rule. The sample-report request requires contact details; none were supplied. A different glycomic risk panel does not validate this service. [M12; C05] |
| Tally Health · TallyAge | Cheek-swab DNA methylation age report; membership/advice products are separately marketed. [C08] | CheekAge research includes paired collections and an incomplete-feature blood mortality adaptation. Exact TallyAge-to-CheekAge, current assay/laboratory and preprocessing equivalence remain unpinned. These are not two independent consumer-service trials. [M23; M24] |
| InsideTracker · InnerAge 2.0 | Proprietary age inference from routine blood measurements. Current Membership + Ultimate pages offer it as an optional add-on, including an eligible existing-draw route. [C10; F03; F05] | Help permits multiple biomarker combinations, including sparse subsets. The listing’s 17-male/13-female marker description is not a guarantee that every calculation uses the full set. Record the inputs actually used on each report; this is not published Phenotypic Age or KDM. [C10; F05] |
Ownership is not assay identity. Tally’s policy states that IE Tally Holdings, LLC, a TruDiagnostic affiliate, acquired the brand/business assets on 19 March 2026; the policy is effective 29 April 2026. This is a newly documented earlier event, not a September acquisition. Two brands therefore do not establish independent-provider confirmation, but affiliation does not prove identical specimens, laboratories, weights or results. [C09]
The shop-linked Advanced TruAge sample has a June 2025 report date. It illustrates a report format, not the exact version supplied by a September 2026 purchase. No sample identity or personal interpretation is reproduced here. [F07]
A publication is not automatically validation of the whole product
TruAge: OMICmAge’s version of record appeared on 25 February 2026; Systems Age’s on 15 September 2025. Neither should be described here as merely a preprint. OMICmAge discloses sponsored research, company involvement and patent interests. External-cohort evidence is not the same as an independent commercial evaluation. Deployment uses DNAm-derived inputs, not direct measurement of the customer’s entire proteome and metabolome. [M21; M22]
TallyAge: the later CheekAge mortality analysis used a blood adaptation with incomplete features and standardized delta scores. It is relevant prognostic evidence but not proof that one current consumer cheek swab forecasts an individual death date or that the membership causes benefit. The researchers’ commercial affiliation must remain visible. [M23; M24]
GlycanAge: a small longitudinal subset in the original research had heterogeneous trajectories. That does not supply a universal current-service retest response or error bound. Seller claims about triplicates or a one-year margin need to identify whether they concern assay precision, age prediction or individual change. [M12; C04]
InnerAge: an InsideTracker-associated 2018 study followed 1,032 repeat-testing customers and examined laboratory changes, not validation of the current proprietary InnerAge 2.0 score. No tested intervention associations survived its multiple-testing correction. Observational limits remain; the linked correction notice’s text was not obtained, so its substance is not asserted. [F08]
Price, burden and commitments
| Offering | Acquisition price and timing | Commitment and access boundary |
|---|---|---|
| TruAge | Standalone $499; TruAge/TruHealth bundle $849. Prepaid US return. Shop: 3–4 weeks after lab receipt; provider page: 2–4 weeks. [C01; C02] | A four-test annual subscription is advertised, but its full recurring terms and price were not established. International eligibility, taxes and delivered totals remain unverified. |
| GlycanAge | No reliable current price/currency recovered. Kit, return process and consultation; approximately 3–4 weeks advertised. [C04; C05] | Dynamic-shop access does not justify reusing an old price or inferring withdrawal. Country-specific fulfillment, sample-report contents and all-in cost remain unverified. |
| TallyAge | Standalone $249, free-shipping language and approximately 6–8 weeks. [C08] | Terms limit purchase to adult residents of the 50 US states/DC, exclude APO shipment and require an account for results. Current optional membership total was not verified; a standalone kit is not automatically a mandatory membership. [C09] |
| InnerAge / InsideTracker | InnerAge listing: $249 standalone / $99 Ultimate add-on. Current Membership + Ultimate $489; InnerAge optional. Mobile draw +$119. [C10; F03] | The current route strengthens availability evidence beyond the older listing, but checkout remains untested. Membership has annual renewal language; the bundle is not a permanently one-off lab fee. Exact renewal/cancellation terms and eligibility remain unverified. |
With the displayed $119 mobile draw: $707, before unverified extras. The $99 add-on alone is not the cost of the complete service.
That is a lower acquisition burden, not proof that the score adds useful information beyond the laboratory results already held.
Two unchanged standalone TruAge prices total $998; two TallyAge prices total $498, before unverified extras. These sums price neither a subscription nor an evidence-based retest schedule. Include collection, shipping, taxes, interpretation, renewals and failed-sample costs; no trustworthy all-in four-way price comparison is available. [C02; C08]
Refunds, renewal and failed samples are different questions
| Provider | Inspected terms | What remains separate |
|---|---|---|
| TruDiagnostic | Policy effective 3 August 2026: sales, including annual subscriptions, generally final; specified replacements and full refund when both initial and second viable samples fail because of laboratory error. [F01] | Not an unconditional satisfaction guarantee. Renewal cancellation mechanics and performance under every shipping condition are not established. |
| GlycanAge | Policy updated 2 September 2026: sealed unused kits have a 14-day cancellation window after receipt and a return deadline. Opened/sent samples are generally excluded except specified fault/failure remedies. Consultation usable within 60 days after results. [F02] | Not a refund because an age is unexpected or an indefinite consultation entitlement. Exact circumstances and statutory rights were not adjudicated. |
| Tally | Program terms: monthly automatic renewal, nonrefundable membership fees and cancellation at least three days before the next period. [C09] | Program provisions do not establish that a standalone kit requires membership. Standalone refund/failure terms were not fully established. |
| InsideTracker | Store policy describes refund requests within 30 days, before testing is completed, with later/completed-test restrictions. [F04] | Not a free trial after receiving results. Annual-membership renewal/cancellation still needs transaction-specific confirmation. |
These effective dates precede the initial 21 September review. Fuller documentation is not evidence that the policies changed during this update. Disclosures are not findings about actual fulfillment, refunds or legal compliance.
Data access, retention and consent
Ask about five different objects: the physical sample, raw assay files, processed measurements, derived scores/reports, and research or aggregated derivatives. Account deletion, research withdrawal and marketing opt-out need not affect the same objects. A PDF of age numbers does not reproduce the assay-to-score calculation.
| Provider | Public policy description | Unverified objects or operations |
|---|---|---|
| TruDiagnostic | Access/download of processed information and research withdrawal. Withdrawal does not undo completed work; exclusion concerns newly starting research after a stated delay. Deletion/sample discard has legal, laboratory and research qualifications. [C03] | Raw IDAT/beta export, fees, complete metadata, effects on every derivative and current operational deletion/retention behavior. |
| Tally | Affiliate sharing and post-account retention, including three years for health/wellness information, seven years for transactions and potentially indefinite aggregated/deidentified retention. Genetic/biometric retention has separate exceptions. [C09] | Raw assay export, sample destruction and actual enrollment choices. Terms authorize future research while the policy also refers to consented research; the consent/withdrawal flow was not exercised. |
| GlycanAge | Terms describe processing outside the customer’s country; substantive privacy text still rendered as a loading placeholder. [C06] | Research opt-in/withdrawal, raw glycan/report export, physical-sample disposal, retention and deletion coverage. A cookie date is not the missing privacy-policy date. |
| InsideTracker | Privacy route was reached without sufficient substantive policy text. [C11] | Distinct rights/retention for lab values, uploaded data, derived scores and research use. Security/compliance badges do not establish those terms. |
“Does not sell” is not “does not share.” Unread policy content is not proof of absent protections, and disclosure is not verification of operations. No account, consent dialog, export or deletion mechanism was tested. Research reuse needs usable raw/processed data, assay and model metadata, and permission—not just a downloadable report.
Ask what precision means for the report you will receive
CheekAge has substantive paired-collection evidence. The developer-affiliated paper reports 190 replicate pairs from two cheek collections within 24 hours, with mean replicate error of approximately 0.85 years for the full model and a separate cross-validated value. This is not development age-prediction MAE, a 95% distribution of intervisit differences, or independent verification of the current TallyAge service. It cannot supply a personal meaningful-change threshold. [M23]
OMICmAge’s reported 0.998 ICC using 30 replicates likewise does not supply a collection-to-report personal-change interval. TruDiagnostic describes multiple platforms and a paired reference resource, so “no bridging evidence” would overstate the gap. The unresolved question is a frozen, output-level bridge and absolute residual error applicable to the old and new reports being compared. [M21; F06]
A split after DNA processing covers fewer stages than two complete collections. GlycanAge’s triplicate/one-year-margin language and a seller’s same-sample reproducibility percentage need their metric, coverage and split point specified; neither converts itself into score-year intervisit uncertainty. [C02; C04; R03; R05]
Illustrations and improvement percentages are not controlled outcomes
TruAge’s provider page labels its before/after profiles illustrative, not actual patient results. Tally advertises that over 62% of members lowered epigenetic age within 12 months, averaging more than two years. InnerAge’s listing describes improvement among initially high-scoring customers, while current Ultimate copy uses a broader customer percentage. The inspected record does not establish common denominators, attrition, version continuity or untreated comparison groups; these are not interchangeable populations. [C01; C08; C10; F03]
Selection for a high first score, selective retesting, concurrent behavior changes, transient physiology, changing inputs and regression to the mean can affect before/after summaries. Their contribution was not quantified here. Ask for the eligible and retested denominators, fixed pipeline, comparison group and uncertainty before interpreting a customer percentage as benefit. The CALERIE group result does not supply an individual customer’s counterfactual.
| Ask the seller | What a useful answer would specify | What would not settle it |
|---|---|---|
| What exactly was reported at each visit? | Raw score, score-minus-age gap, age-regression residual or pace; model/report version, specimen, actual marker subset, assay generation, imputation, normalization and reference calibration; whether old reports were reprocessed. | A brand name or the label “biological age” without the output definition. |
| Where did the precision experiment begin? | Split point, independent participant count, separate collections versus stored-sample duplicates, shipping/extraction/assay/computation stages, and matched timing and population. | Triplicates of one assay stage presented as precision of the whole collection-to-report service. |
| How were old and new methods bridged? | Paired representative specimens through both complete pipelines; a bridge fitted on designated data and evaluated independently for bias and remaining disagreement; disclosure of historical-report recalculation. | High correlation alone, or separately recentering both versions so their average residuals match. |
| What uncertainty applies to my reported change? | Absolute difference variance and bias in score-years, gap-years or pace units, as applicable; collection-to-report and intervisit conditions; whether an interval describes a group mean or an individual difference. | Cross-sectional age-prediction error, a mean-offset confidence interval or a seller’s preferred retest schedule used as a personal threshold. |
These are proposed questions derived from the replicate and platform evidence, not claims that a named seller uses the studied pipeline. The same-DNA platform example is not a conversion for purchased reports. Clinical-laboratory and proteomic change thresholds additionally need score-level covariance or full-pipeline repeated predictions; individual analyte CVs or protein ICCs do not supply them. [R03; R05]
Before paying—or paying again
- Define the decision.
What will the report add beyond information you already have? General advice available without testing does not itself establish the test’s value.
- Ask for the exact output and evidence.
Which assay, model/version, actual input subset and report are delivered? Has a historical report been reprocessed? Does the validation use that specimen and full pipeline in a relevant population?
- Ask what a repeat can resolve.
Use the precision and bridging questions above. Ask for uncertainty in the actual reported units, not a laboratory badge, age correlation or suggested retest interval.
- Check the whole commitment.
Confirm the base package plus add-on, renewal, eligibility, delivered cost, failed-sample remedies and cancellation. Ask separately about sample disposal, raw files/metadata, processed data, reports and research derivatives.
Bottom line: none of the inspected material establishes long-term outcome benefit from the purchased testing-and-advice package versus a realistic no-test alternative. That is not a finding of failure or an allegation against a seller. It means “no additional test for this decision” remains a reasonable option. For a report already in hand, start with interpretation rather than score optimization.
Sources and reading limits
Source labels distinguish primary research, seller documents and implementation notes. Seller and F-source observations are from 28 September 2026 unless marked historical. M21/M23/M24 received the described follow-up inspection; other M observations remain inherited from 21 September, and R measurement sources from 22 September. Policy effective dates and event dates are not retrieval dates. No purchase, private report, export or consent flow was tested.
C01. TruDiagnostic: About TruAge. Seller outputs, specimen, intended use, turnaround and explicit illustrative-case disclaimer inspected; not patient outcome evidence.
C02. TruAge shop. Displayed prices, return/turnaround, four-test annual offering and reproducibility language inspected; no checkout or complete recurring-contract test.
C03. TruDiagnostic privacy policy. Processed-data access, research withdrawal and deletion/sample qualifications inspected. Exact raw export and operational behavior untested.
C04. GlycanAge overview. Seller specimen, service, timing and precision language inspected; no independent service test.
C05. GlycanAge shop and sample-report request. Reliable price/currency did not render; report form requested contact details. No details supplied or sample report acquired.
C06. GlycanAge terms and privacy route. Processing/failure terms inspected; privacy body remained a loading placeholder. The separately retrieved refund policy is F02, not proof that privacy text was obtained.
C07. Tally Health overview. Historical programme/retest descriptions inspected on 21 September 2026. Current standalone and legal evidence is in C08/C09.
C08. TallyAge standalone listing. Price, specimen, shipping/timing and member-improvement claim inspected; deployed artifact and underlying customer analysis not obtained.
C09. Tally privacy and terms, effective 29 April 2026. March-19 acquisition, affiliate sharing, retention, adult/US eligibility, account/research provisions and Program renewal/cancellation inspected. Consent operations, raw export and standalone refund conditions unverified.
C10. InnerAge listing. Displayed standalone/add-on prices, marker-count and high-baseline customer claims inspected. Current Ultimate route is F03; no purchase or proprietary-formula recovery.
C11. InsideTracker privacy route. Insufficient substantive policy body retrieved; not evidence that protections are absent.
M05. Belsky et al. (2022), DunedinPACE Primary longitudinal target, normalization, technical/cross-platform reliability and relevant validation text inspected; model not executed.
M12. Krištić et al. (2014; online 2013), Glycans are a novel biomarker of chronological and biological ages Primary development, external-population and small longitudinal-subset results; not validation of a pinned 2026 product.
M21. Chen et al. (2026), OMICmAge, published 25 February. Relevant target/proxy, external-cohort and replicate passages reread on 28 September; prior access/conflict limits retained. Sponsored/company-affiliated research with patent interests, not certification of a purchased service.
M22. Sehgal et al. (2025), Systems Age Version of record: 15 September 2025. Abstract/metadata and primary update linkage inspected; detailed rankings and current product equivalence withheld.
M23. Shokhirev et al. (2024), CheekAge development. Relevant full development, paired-collection, replicate-metric and limitation/conflict passages inspected on 28 September. Tally-affiliated/funded; 190 pairs and mean error describe the studied model, not a pinned consumer service.
M24. Shokhirev et al. (2024), CheekAge mortality adaptation in blood. Relevant incomplete-feature implementation, standardization and mortality passages inspected; no raw predictions rerun. Company-affiliated external-cohort evidence, not a prospective purchased-cheek-service trial.
R03. McEwen et al. (2018), EPIC/450K clock assessment Relevant methods/results/discussion inspected, including normalization and the post-bisulfite-conversion technical split. No raw-array reproduction; its age-error-based heuristic is not adopted as an individual detection threshold.
R05. Tay et al. (2025), DNAm age differences across EPIC versions and specimens Relevant methods/results/conflicts and Supplementary Table S4 inspected. Same extracted DNA, 16 paired samples per specimen, ages 40–60, 14 Chinese participants; EPICv2 imputation was part of the pipeline. Rounded aggregate reconstruction, not raw-data reproduction. Main-text/S4 and normalization-reference discrepancies remain unresolved. Disclosures include clock-foundation and advisory roles.
F01. TruDiagnostic returns/refunds, effective 3 August 2026. Final-sale, replacement and laboratory-failure clauses inspected; no legal enforceability finding.
F02. GlycanAge refund policy, updated 2 September 2026. Sealed/opened-kit, failure and consultation-window provisions inspected; no refund experiment.
F03. InsideTracker store and Membership + Ultimate. Bundle, optional InnerAge/mobile draw, customer claim and annual-renewal language inspected; transaction totals and recurring conditions unverified.
F04. InsideTracker refund policy. Timing and completed-test exclusions inspected; no purchase/refund test.
F05. InsideTracker required-biomarker help and InnerAge help. Multiple permitted combinations and existing-test add-on description inspected. Relative update labels are not exact change dates.
F06. TruDiagnostic array platforms. Multiple-array and paired-reference claims inspected, not a numerical independent output-level bridge reproduction.
F07. Advanced TruAge sample PDF. Historical June-2025 report metadata and selected pages inspected in the source review; not a current purchased report, patient dataset or validation study.
F08. Westerman et al. (2018), repeated clinical biomarker study. Relevant methods/results, multiplicity and observational limitations inspected; company affiliations retained. Linked correction DOI 10.1038/s41598-018-35249-y was not retrieved; its substance is not asserted.
Next: Interpret a changed or conflicting result or follow the worked purchase decision.